For Healthcare Professionals Outside the US
Pyrexia may be managed with dose interruption or antipyretic treatment, which generally can allow treatment to resume.1,2
For patients with BRAF V600+ unresectable or metastatic melanoma3,4:
For patients with BRAF V600+ NSCLC5:
Pyrexia was one of the most common adverse reactions, reported by 55% of patients receiving Tafinlar + Mekinist
2 patients discontinued Tafinlar + Mekinist due to pyrexia
References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 3. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451. 4. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 5. Tafinlar [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017.